Hims & Hers Health, Inc. announced a proposed private offering of convertible senior notes. The company intends to offer $300 million aggregate principal amount. These notes mature on June 1, 2032. The private placement targets qualified institutional buyers under Rule 144A.
The firm expects to grant initial purchasers an option for more notes. This option covers up to $45 million in additional principal. It must settle within 13 days from the initial issuance date. The company will use the capital to secure financial flexibility.
Net proceeds will support an international expansion strategy. This expansion includes the proposed acquisition of Eucalyptus. The Eucalyptus transaction should close in mid-2026. The completion remains subject to customary closing conditions.
The business also plans an extensive AI-driven platform investment. Funds will scale artificial intelligence capabilities to enhance consumer experiences. Capital will also flow into technology and fulfillment infrastructure. This infrastructure investment aims to drive future cost efficiencies. The technology will better leverage the closed-loop data ecosystem of the business.
Financial Structure and Capped Call Details
The notes represent senior, unsecured obligations. Interest will accrue and require semi-annual payments in arrears. Noteholders can convert their positions during specified periods under certain circumstances.
Hims & Hers holds the option to settle conversions using different methods. It can deliver cash, shares of Class A common stock, or a combination. The interest rate and initial conversion rate will be set at pricing.
The company can redeem the notes for cash starting June 6, 2029. This option extends until the 25th scheduled trading day before maturity. Redemption requires the Class A common stock price to exceed 130% of the conversion price.
Corporate events that cause a fundamental change allow noteholders to demand a repurchase. The company would pay cash equal to the principal plus accrued interest.
Hims & Hers expects to enter privately negotiated capped call transactions. These agreements with option counterparties aim to reduce potential stock dilution. They can also offset potential cash payments above the principal amount.
Counterparties enter into derivative transactions or acquire Class A Common Stock to initiate hedges. This takes place simultaneously or soon after pricing. This may have an impact on the trading price of the stock and notes.
The hedging adjustments may go on until maturity in the secondary market. This can impact the conversion capacity and ultimate consideration of the noteholders. The notes and underlying shares lack registration under the Securities Act.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
